Get to know our clinical trials
Clinical trial to evaluate the safety, pharmacokinetics and activity of XmAb24306 in combination with cevostamab in patients with relapsed/refractory multiple myeloma.
THE OBJECTIVE OF THIS STUDY IS TO EVALUATE XMAB24306 AT DIFFERENT DOSES TO DETERMINE WHETHER IT IS SAFE IN COMBINATION WITH CEVOSTAMAB AND HOW IT IS PROCESSED BY THE BODY. THE STUDY WILL ALSO EVALUATE CEVOSTAMAB IN MONOTHERAPY.
Technical Summary
- PHASE IB, OPEN-LABEL, MULTICENTER, MULTICENTER, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF XMAB24306 IN COMBINATION WITH CEVOSTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. IMMUNOTHERAPY.
- Code EudraCT: 2022-001204-18
- Protocol number: GO43980
- Promoter: Genentech, Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.